Hiroyuki Uchida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroyuki Uchida has a total of 622 co-authors. Here are the top co-authors by number of shared publications:
Masaru Mimura
Department of Neuropsychiatry Keio University School of Medicine Tokyo Japan
67 shared publications- Takefumi Suzuki
Department of Neuropsychiatry University of Yamanashi Faculty of Medicine Chuo Yamanashi Japan
32 shared publications - Shinichiro Nakajima
Department of Neuropsychiatry, Keio University School of Medicine, Japan
28 shared publications Takefumi Suzuki
Department of Neuropsychiatry University of Yamanashi Faculty of Medicine Yamanashi Japan
28 shared publicationsHideaki Tani
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
22 shared publications- Masaru Mimura
Department of Neuropsychiatry Keio University School of Medicine Tokyo Japan
20 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by MDPI AG in Preprints.org
From Lesion Network Mapping in Humans to Causal Circuit Validation in Animals for Defining Neuromodulation Targets: A Narrative Review
Neuromodulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), have demonstrated efficacy across several neuropsychiatric disorders, yet identifying symptom-specific and biologically informed stimulation targets remains a major challenge. Lesion network mapping (LNM) addresses this problem by treating focal brain lesions as natural perturbations and mapping anatomically heterogeneous lesion locations onto normative connectomes to identify convergent symptom-relevant circuits. Since its introduction in 2015, LNM has generated candidate neuromodulation targets across diverse neurological and psychiatric conditions, with several studies showing overlap between lesion-derived networks, independent neuroimaging findings, and therapeutic neuromodulation targets. However, these observations do not establish whether the identified networks connected to lesion sites are causally responsible for symptom expression or how they should be therapeutically modulated. Because LNM relies on correlation-based connectivity measures, it cannot determine which circuit components or pathways causally mediate the relevant symptom, or whether candidate neuromodulation targets should be activated or inhibited. We therefore propose a translational framework in which LNM-derived circuit hypotheses are examined through cross-species anatomical and functional mapping, region-, cell-, and projection-specific perturbation in animal models, and concurrent behavioral and whole-brain functional readouts, before clinical evaluation. This framework positions LNM as a tool for identifying candidate circuits that are first tested in animal models for causal relevance and perturbation direction, and then evaluated clinically for therapeutic relevance.
- 30 October 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Lesion Network Mapping in Humans to Causal Circuit Validation in Animals for Defining Neuromodulation Targets: A Narrative Review
Neuromodulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), have demonstrated efficacy across several neuropsychiatric disorders, yet identifying symptom-specific and biologically informed stimulation targets remains a major challenge. Lesion network mapping (LNM) addresses this problem by treating focal brain lesions as natural perturbations and mapping anatomically heterogeneous lesion locations onto normative connectomes to identify convergent symptom-relevant circuits. Since its introduction in 2015, LNM has generated candidate neuromodulation targets across diverse neurological and psychiatric conditions, with several studies showing overlap between lesion-derived networks, independent neuroimaging findings, and therapeutic neuromodulation targets. However, these observations do not establish whether the identified networks connected to lesion sites are causally responsible for symptom expression or how they should be therapeutically modulated. Because LNM relies on correlation-based connectivity measures, it cannot determine which circuit components or pathways causally mediate the relevant symptom, or whether candidate neuromodulation targets should be activated or inhibited. We therefore propose a translational framework in which LNM-derived circuit hypotheses are examined through cross-species anatomical and functional mapping, region-, cell-, and projection-specific perturbation in animal models, and concurrent behavioral and whole-brain functional readouts, before clinical evaluation. This framework positions LNM as a tool for identifying candidate circuits that are first tested in animal models for causal relevance and perturbation direction, and then evaluated clinically for therapeutic relevance.
- Open Access
- 14 October 2026
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 212, 113022
Exploring the association between Brief Evaluation of Psychosis Symptom Domains and HbA1c in patients with schizophrenia and schizoaffective disorder
- 14 October 2026
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 212, 113022
Open AccessExploring the association between Brief Evaluation of Psychosis Symptom Domains and HbA1c in patients with schizophrenia and schizoaffective disorder
- Open Access
- 31 August 2026
- Published by Springer Nature in Schizophrenia
Morality, voices, and self at the edge of reality: a narrative analysis of delusional experiences and pathways to care in schizophrenia
Background: Delays in seeking help are common in schizophrenia and are associated with negative outcomes. In addition to structural barriers, there is growing evidence that subjective interpretations of psychotic experiences, including delusions, voices, and religious or spiritual attributions, play a crucial role in recognizing symptoms and seeking care. Objective: This study explores how individuals diagnosed with schizophrenia describe the onset of psychosis, interpret their experiences, and navigate pathways toward or away from psychiatric care. Methods: We conducted semi-structured interviews with 16 individuals with schizophrenia. Data were analyzed using inductive thematic coding and narrative analysis to capture the experiential and interpretive dimensions of psychosis and help-seeking behaviors. Results: We present three interconnected narrative themes that address the research question. First, participants’ experiences revolved around a moral dichotomy involving themes such as God and the devil, good and evil, and power and weakness. Second, participants described ‘nearly real’ sensory experiences, including voices and delusions ranging from familiar to imperative and fearsome. Third, the narratives revealed an ongoing struggle between private and shared realities, involving efforts to define boundaries and regain coherence. These experiential frameworks actively shaped the recognition of symptoms, trust in others, and the timing and direction of seeking help. Conclusions: Psychotic experiences function not only as symptoms but also as organizing narrative forces that influence pathways to care. Narrative-sensitive and metacognitive approaches may improve early engagement and reduce treatment delays.
- 31 August 2026
- Published by Springer Nature in Schizophrenia
Open AccessMorality, voices, and self at the edge of reality: a narrative analysis of delusional experiences and pathways to care in schizophrenia
Background: Delays in seeking help are common in schizophrenia and are associated with negative outcomes. In addition to structural barriers, there is growing evidence that subjective interpretations of psychotic experiences, including delusions, voices, and religious or spiritual attributions, play a crucial role in recognizing symptoms and seeking care. Objective: This study explores how individuals diagnosed with schizophrenia describe the onset of psychosis, interpret their experiences, and navigate pathways toward or away from psychiatric care. Methods: We conducted semi-structured interviews with 16 individuals with schizophrenia. Data were analyzed using inductive thematic coding and narrative analysis to capture the experiential and interpretive dimensions of psychosis and help-seeking behaviors. Results: We present three interconnected narrative themes that address the research question. First, participants’ experiences revolved around a moral dichotomy involving themes such as God and the devil, good and evil, and power and weakness. Second, participants described ‘nearly real’ sensory experiences, including voices and delusions ranging from familiar to imperative and fearsome. Third, the narratives revealed an ongoing struggle between private and shared realities, involving efforts to define boundaries and regain coherence. These experiential frameworks actively shaped the recognition of symptoms, trust in others, and the timing and direction of seeking help. Conclusions: Psychotic experiences function not only as symptoms but also as organizing narrative forces that influence pathways to care. Narrative-sensitive and metacognitive approaches may improve early engagement and reduce treatment delays.
- Open Access
- 6 August 2026
- Published by SAGE Publications in International Journal of Social Psychiatry
Cross-Cultural Comparison of Perceived Stigma in Major Depressive Disorder: The Role of Spiritual Well-Being, Resilience, and Quality of Life in Austria and Japan
Background: Perceived stigma in Major Depressive Disorder (MDD) is a well-established barrier to help-seeking, social functioning, and quality of life. However, little is known about how stigma is shaped by cultural context and which psychosocial resources may buffer its effects. Aims: This study aimed to examine the relationship between perceived stigma and key protective factors – spirituality, resilience, quality of life, and social functioning – in patients with MDD from Austria and Japan. Method: A total of 101 patients diagnosed with MDD (51 from Austria, 50 from Japan) completed validated measures of perceived stigma, spirituality, resilience, quality of life, and social functioning. Correlational analyses, multiple regression, and interaction term models were used to assess the predictive value of psychosocial variables and country moderation effects. Results: Spirituality and resilience were negatively associated with perceived stigma across both samples, though only spirituality significantly predicted stigma in regression analyses, increasing to 48% after controlling for age and depression severity. Country-specific models revealed a stronger predictive power in the Japanese sample. While stigma correlated strongly with reduced quality of life in both groups, its association with social functioning varied by stigma dimension and country. The relationship between resilience and financial insecurity was stronger among Japanese study participants than among Austrian participants. Conclusions: In summary, spirituality emerged as a central protective factor against stigma in MDD patients, particularly in Japan, underscoring its cultural significance. Additionally, our findings reveal a context-specific relationship between economic stress and psychosocial coping strategies. Despite differences in how stigma is expressed across countries, its adverse impact on quality of life was universal. These results suggest that culturally informed approaches can effectively reduce stigma associated with depression.
- 6 August 2026
- Published by SAGE Publications in International Journal of Social Psychiatry
Open AccessCross-Cultural Comparison of Perceived Stigma in Major Depressive Disorder: The Role of Spiritual Well-Being, Resilience, and Quality of Life in Austria and Japan
Background: Perceived stigma in Major Depressive Disorder (MDD) is a well-established barrier to help-seeking, social functioning, and quality of life. However, little is known about how stigma is shaped by cultural context and which psychosocial resources may buffer its effects. Aims: This study aimed to examine the relationship between perceived stigma and key protective factors – spirituality, resilience, quality of life, and social functioning – in patients with MDD from Austria and Japan. Method: A total of 101 patients diagnosed with MDD (51 from Austria, 50 from Japan) completed validated measures of perceived stigma, spirituality, resilience, quality of life, and social functioning. Correlational analyses, multiple regression, and interaction term models were used to assess the predictive value of psychosocial variables and country moderation effects. Results: Spirituality and resilience were negatively associated with perceived stigma across both samples, though only spirituality significantly predicted stigma in regression analyses, increasing to 48% after controlling for age and depression severity. Country-specific models revealed a stronger predictive power in the Japanese sample. While stigma correlated strongly with reduced quality of life in both groups, its association with social functioning varied by stigma dimension and country. The relationship between resilience and financial insecurity was stronger among Japanese study participants than among Austrian participants. Conclusions: In summary, spirituality emerged as a central protective factor against stigma in MDD patients, particularly in Japan, underscoring its cultural significance. Additionally, our findings reveal a context-specific relationship between economic stress and psychosocial coping strategies. Despite differences in how stigma is expressed across countries, its adverse impact on quality of life was universal. These results suggest that culturally informed approaches can effectively reduce stigma associated with depression.
- Open Access
- 3 August 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (12) , 6881-6888
High prevalence of tau pathologies in late-onset psychosis: A PET study
Late-onset psychosis (LOP) exhibits distinct clinical features compared with younger-onset psychosis. Although postmortem and epidemiological studies have suggested an association between LOP and neurodegenerative processes, particularly tauopathies, in vivo evidence remains limited. This study aimed to investigate the involvement of Alzheimer’s disease (AD) and non-AD tauopathies in LOP using amyloid PET and tau PET with florzolotau (18F) ( 18 F-florzolotau; also known as 18 F-APN-1607 or 18 F-PM-PBB3), a tracer capable of detecting a broad range of tau pathologies. Thirty-seven patients with LOP and 47 age-matched controls underwent PET scans with 11 C-PiB and 18 F-florzolotau to assess group differences in amyloid beta (Aβ) and tau accumulation. Diagnostic effects on regional 18 F-florzolotau standardized uptake value ratios (SUVRs) were assessed. Associations between regional SUVRs and cognitive and clinical features were examined separately in Aβ-positive and Aβ-negative subgroups. Patients exhibited significantly higher positivity rates for both Aβ (13 of 37 patients, 35.1%) and tau (24 patients, 64.9%) than controls (one of 47 controls, 2.1% for Aβ and seven controls, 14.9% for tau). A significant diagnostic effect was observed on regional 18 F-florzolotau SUVRs ( P = 0.004), with post-hoc analyses revealing increased tracer retention in the parietal cortex. This diagnostic effect remained robust when the analysis was restricted to Aβ-negative participants ( P = 0.002). Among Aβ-positive patients, greater parietal tau burden was associated with lower Frontal Assessment Battery scores. In conclusion, this in vivo PET study demonstrated a high prevalence of AD-like and non-AD-like tau accumulation patterns in LOP, suggesting that LOP may be associated with heterogeneous tau-related neurodegenerative processes.
- 3 August 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (12) , 6881-6888
Open AccessHigh prevalence of tau pathologies in late-onset psychosis: A PET study
Late-onset psychosis (LOP) exhibits distinct clinical features compared with younger-onset psychosis. Although postmortem and epidemiological studies have suggested an association between LOP and neurodegenerative processes, particularly tauopathies, in vivo evidence remains limited. This study aimed to investigate the involvement of Alzheimer’s disease (AD) and non-AD tauopathies in LOP using amyloid PET and tau PET with florzolotau (18F) ( 18 F-florzolotau; also known as 18 F-APN-1607 or 18 F-PM-PBB3), a tracer capable of detecting a broad range of tau pathologies. Thirty-seven patients with LOP and 47 age-matched controls underwent PET scans with 11 C-PiB and 18 F-florzolotau to assess group differences in amyloid beta (Aβ) and tau accumulation. Diagnostic effects on regional 18 F-florzolotau standardized uptake value ratios (SUVRs) were assessed. Associations between regional SUVRs and cognitive and clinical features were examined separately in Aβ-positive and Aβ-negative subgroups. Patients exhibited significantly higher positivity rates for both Aβ (13 of 37 patients, 35.1%) and tau (24 patients, 64.9%) than controls (one of 47 controls, 2.1% for Aβ and seven controls, 14.9% for tau). A significant diagnostic effect was observed on regional 18 F-florzolotau SUVRs ( P = 0.004), with post-hoc analyses revealing increased tracer retention in the parietal cortex. This diagnostic effect remained robust when the analysis was restricted to Aβ-negative participants ( P = 0.002). Among Aβ-positive patients, greater parietal tau burden was associated with lower Frontal Assessment Battery scores. In conclusion, this in vivo PET study demonstrated a high prevalence of AD-like and non-AD-like tau accumulation patterns in LOP, suggesting that LOP may be associated with heterogeneous tau-related neurodegenerative processes.
- Open Access
- 7 July 2026
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 29 (8)
In memoriam: Professor Shigeto Yamawaki (January 15, 1954–June 8, 2026)—a visionary leader connecting Japan, Asia, and the world
- 7 July 2026
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 29 (8)
Open AccessIn memoriam: Professor Shigeto Yamawaki (January 15, 1954–June 8, 2026)—a visionary leader connecting Japan, Asia, and the world
- 7 July 2026
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 59 (06) , 367-375
Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial
While the rapid and robust effects of ketamine on depressive symptoms in treatment-resistant depression (TRD) have been demonstrated, the influence of ketamine treatment on cognitive function has not yet been fully elucidated. We aimed to evaluate the effects of ketamine treatment on cognitive function as part of a study that investigated the efficacy of repeated ketamine administration in patients with TRD. In addition, we conducted an exploratory analysis to examine whether baseline cognitive function was associated with ketamine response. In this double-blind, randomized, placebo-controlled study, 34 Japanese TRD patients were enrolled and assigned randomly into either ketamine or placebo group. They received ketamine 0.5 mg/kg or saline intravenously for four doses. Objective and subjective cognitive functions were evaluated with a comprehensive assessment battery before and after the intervention. We also assessed depressive symptoms with the Montgomery-Åsberg Depression Rating Scale (MADRS). The response was defined by at least a 50% reduction in the total MADRS score. No significant differences were found between the ketamine and placebo groups on objective or subjective cognitive function scale score changes. Moreover, ketamine responders showed a significant improvement in subjective cognitive function compared to non-responders. The participants who demonstrated less inhibitory control at baseline showed greater MADRS score reductions after the ketamine treatment. Repeated ketamine administration did not significantly deteriorate cognitive function compared to placebo, which supports a possible cognitive safety profile in patients with TRD. In addition, baseline impaired cognitive control may be associated with ketamine response.
- 7 July 2026
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 59 (06) , 367-375
Association between Intravenous Ketamine Treatment and Cognitive Function in Patients with Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial
While the rapid and robust effects of ketamine on depressive symptoms in treatment-resistant depression (TRD) have been demonstrated, the influence of ketamine treatment on cognitive function has not yet been fully elucidated. We aimed to evaluate the effects of ketamine treatment on cognitive function as part of a study that investigated the efficacy of repeated ketamine administration in patients with TRD. In addition, we conducted an exploratory analysis to examine whether baseline cognitive function was associated with ketamine response. In this double-blind, randomized, placebo-controlled study, 34 Japanese TRD patients were enrolled and assigned randomly into either ketamine or placebo group. They received ketamine 0.5 mg/kg or saline intravenously for four doses. Objective and subjective cognitive functions were evaluated with a comprehensive assessment battery before and after the intervention. We also assessed depressive symptoms with the Montgomery-Åsberg Depression Rating Scale (MADRS). The response was defined by at least a 50% reduction in the total MADRS score. No significant differences were found between the ketamine and placebo groups on objective or subjective cognitive function scale score changes. Moreover, ketamine responders showed a significant improvement in subjective cognitive function compared to non-responders. The participants who demonstrated less inhibitory control at baseline showed greater MADRS score reductions after the ketamine treatment. Repeated ketamine administration did not significantly deteriorate cognitive function compared to placebo, which supports a possible cognitive safety profile in patients with TRD. In addition, baseline impaired cognitive control may be associated with ketamine response.
- Open Access
- 25 May 2026
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 149, 152719
Multi-day heart rate variability monitoring via Holter electrocardiogram for depression detection: Clinical validation and translational challenges
- 25 May 2026
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 149, 152719
Open AccessMulti-day heart rate variability monitoring via Holter electrocardiogram for depression detection: Clinical validation and translational challenges
- Open Access
- 7 May 2026
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 29 (8)
Global Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next Decade
Background: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. Methods: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence, genetics, artificial intelligence (AI), and implementation/global-access themes that are endorsed by international societies. Results: Therapeutic gains include rapid-acting drugs for treatment-resistant depression (intranasal esketamine); psychedelic-assisted therapy for posttraumatic stress disorder and depression; neuroactive steroid γ-aminobutyric acid-A receptor positive allosteric modulators (brexanolone, zuranolone) for postpartum depression; non-dopaminergic muscarinic agonists (xanomeline–trospium) for schizophrenia; orexin receptor antagonists for insomnia; and anti-amyloid monoclonal antibodies (lecanemab, donanemab) for early Alzheimer’s disease. Persistent barriers include high mid-/late-stage attrition that is driven by placebo effects, subjective endpoints, and preclinical-to-clinical gaps; regulatory and economic headwinds; and limited generalizability from tightly run trials. Emerging enablers include adaptive/platform designs, digital health technologies, patient-reported outcomes, and clinical outcome assessments, real-world evidence (RWE), AI/machine learning (ML), genetics for target de-risking and biomarker-guided stratification, and publicly accessible large CNS relevant biological datasets. Conclusions: To convert momentum into durable progress, we recommend: (i) deeper academia–industry/stakeholder collaboration and sustained funding for high-risk/high-reward science from industry, governments and non-for profit foundations; (ii) modernized regulation (flexible evidentiary paths, novel endpoints, and clear guidance on adaptive/platform trials); (iii) data-driven development integrating RWE, AI/ML, and precision medicine; (iv) the adoption of Neuroscience-based Nomenclature (NbN); and (v) a global-access mandate with essential-medicine inclusion, equitable pricing/licensing, capacity building, tele-enabled mental health, and geographically diverse research. Aligning scientific innovation with implementation and equity can accelerate translation and ensure new treatments benefit patients worldwide.
- 7 May 2026
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 29 (8)
Open AccessGlobal Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next Decade
Background: Over the past decade, neuropsychopharmacology has shifted from stagnation to momentum, with first-in-class mechanisms and biomarker-enabled trials spanning psychiatry and neurology. Methods: We narratively synthesized advances from 2013 to 2026 across central nervous system (CNS) discovery and development, including pivotal trials, regulatory actions, digital/real-world evidence, genetics, artificial intelligence (AI), and implementation/global-access themes that are endorsed by international societies. Results: Therapeutic gains include rapid-acting drugs for treatment-resistant depression (intranasal esketamine); psychedelic-assisted therapy for posttraumatic stress disorder and depression; neuroactive steroid γ-aminobutyric acid-A receptor positive allosteric modulators (brexanolone, zuranolone) for postpartum depression; non-dopaminergic muscarinic agonists (xanomeline–trospium) for schizophrenia; orexin receptor antagonists for insomnia; and anti-amyloid monoclonal antibodies (lecanemab, donanemab) for early Alzheimer’s disease. Persistent barriers include high mid-/late-stage attrition that is driven by placebo effects, subjective endpoints, and preclinical-to-clinical gaps; regulatory and economic headwinds; and limited generalizability from tightly run trials. Emerging enablers include adaptive/platform designs, digital health technologies, patient-reported outcomes, and clinical outcome assessments, real-world evidence (RWE), AI/machine learning (ML), genetics for target de-risking and biomarker-guided stratification, and publicly accessible large CNS relevant biological datasets. Conclusions: To convert momentum into durable progress, we recommend: (i) deeper academia–industry/stakeholder collaboration and sustained funding for high-risk/high-reward science from industry, governments and non-for profit foundations; (ii) modernized regulation (flexible evidentiary paths, novel endpoints, and clear guidance on adaptive/platform trials); (iii) data-driven development integrating RWE, AI/ML, and precision medicine; (iv) the adoption of Neuroscience-based Nomenclature (NbN); and (v) a global-access mandate with essential-medicine inclusion, equitable pricing/licensing, capacity building, tele-enabled mental health, and geographically diverse research. Aligning scientific innovation with implementation and equity can accelerate translation and ensure new treatments benefit patients worldwide.
- Open Access
- 30 April 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (2) , e70125
Glutathione‐Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta‐Analysis
Recently, an increasing number of studies have reported abnormal levels of glutathione (GSH)‐related metabolites and enzyme activities in neuroimaging and peripheral samples in patients with depression, indicating abnormalities in the GSH cycle in patients with depression. However, the abnormalities in the GSH cycle have not been comprehensively investigated. Here, we conducted a systematic review and meta‐analysis to compare the levels of GSH‐related metabolites (GSH and GSH disulfide [GSSG]) and the activities of GSH‐related enzymes (Glutathione‐peroxidase [GPx], GSH reductase [GR], glutamate‐cysteine ligase [GCL], GSH synthetase [GS], and GSH S‐transferase [GST]) between patients with depression and healthy controls (HC). The search was performed with MEDLINE, Embase, and PsychINFO. The inclusion criteria were studies comparing levels of GSH‐related metabolites and enzyme activities between patients with depression and HC. Standardized mean differences were calculated to assess group differences. Thirty studies met the eligibility criteria, which included 1019 patients and 947 HC. Our meta‐analysis indicated significantly decreased activity of GPx in patients with depression compared with HC, while the levels of GSH and GR were not significantly different between the groups. Because no studies, or an insufficient number of studies, have been conducted on GSSG, GST, GCL, and GS, meta‐analyses were not performed for these metabolites and enzyme activities. Our findings suggest that abnormal cycling of the GSH system, particularly decreased GPx activity, is involved in the pathophysiology of depression and may serve as a potential biomarker for this illness. Furthermore, given that no or insufficient studies have been conducted on GSSG, GST, GCL, and GS, this study highlights the need for further research to fully elucidate the GSH cycle in patients with depression.
- 30 April 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (2) , e70125
Open AccessGlutathione‐Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta‐Analysis
Recently, an increasing number of studies have reported abnormal levels of glutathione (GSH)‐related metabolites and enzyme activities in neuroimaging and peripheral samples in patients with depression, indicating abnormalities in the GSH cycle in patients with depression. However, the abnormalities in the GSH cycle have not been comprehensively investigated. Here, we conducted a systematic review and meta‐analysis to compare the levels of GSH‐related metabolites (GSH and GSH disulfide [GSSG]) and the activities of GSH‐related enzymes (Glutathione‐peroxidase [GPx], GSH reductase [GR], glutamate‐cysteine ligase [GCL], GSH synthetase [GS], and GSH S‐transferase [GST]) between patients with depression and healthy controls (HC). The search was performed with MEDLINE, Embase, and PsychINFO. The inclusion criteria were studies comparing levels of GSH‐related metabolites and enzyme activities between patients with depression and HC. Standardized mean differences were calculated to assess group differences. Thirty studies met the eligibility criteria, which included 1019 patients and 947 HC. Our meta‐analysis indicated significantly decreased activity of GPx in patients with depression compared with HC, while the levels of GSH and GR were not significantly different between the groups. Because no studies, or an insufficient number of studies, have been conducted on GSSG, GST, GCL, and GS, meta‐analyses were not performed for these metabolites and enzyme activities. Our findings suggest that abnormal cycling of the GSH system, particularly decreased GPx activity, is involved in the pathophysiology of depression and may serve as a potential biomarker for this illness. Furthermore, given that no or insufficient studies have been conducted on GSSG, GST, GCL, and GS, this study highlights the need for further research to fully elucidate the GSH cycle in patients with depression.